Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
385 people get PJP articles and Market Currents by email alert.
Get email alerts on PJP »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
The Best Pharmaceutical InvestmentsCatalyst Investments • Wed, Mar 20 -
-
-
-
-
-
-
-
Election Could Make Or Break Health Care ETFsTom Lydon • Tue, Sep 18, 2012 -
-
-
-
-
-
3 Dynamic ETFs For A Risk-Off WorldGary Gordon • Wed, May 23, 2012
-
Biotech ETFs For An M&A BoomTom Lydon • Wed, May 16, 2012
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
The Best Pharmaceutical InvestmentsCatalyst Investments • Wed, Mar 20
-
-
-
-
-
-
-
Election Could Make Or Break Health Care ETFsTom Lydon • Tue, Sep 18, 2012
-
-
-
-
-
-
3 Dynamic ETFs For A Risk-Off WorldGary Gordon • Wed, May 23, 2012
-
Biotech ETFs For An M&A BoomTom Lydon • Wed, May 16, 2012
-
There are no Transcripts on PJP.
-
at MarketWatch.com (Apr 2, 2012)
-
at MarketWatch.com (Sep 6, 2011)
PJP vs. ETF Alternatives
PJP Description
The PowerShares Dynamic Pharmaceuticals Portfolio (Fund) is based on the Dynamic Pharmaceuticals Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
See more details on sponsor's website
See more details on sponsor's website
Sector: Healthcare
Country: United States
Key Info
- In Your Portfolio: A Guide to Sector ETFs, A Guide to Healthcare, Pharma and Biotech ETFs
- Asset Class Performance: Themes & Subsectors, Sectors
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, July 21, 2011, 8:20 AM Shares of Protalix (PLX) +4.4% premarket after a report says the firm will file a request with the FDA within days for approval of the firm's Gaucher's disease treatment Uplyso. Comment! [Healthcare, On the Move]
- Wednesday, July 20, 2011, 2:24 PM Abbott Labs (ABT -0.5%) reports prescriptions for its drug Niaspan fell 5% from the level six weeks ago when a study was released showing the medicine failed to prevent heart attacks. The firm told analysts on a conference call this morning the price of Niaspan was raised earlier this year, offsetting the decline in prescriptions. Comment! [Healthcare]
- Monday, July 18, 2011, 3:00 PM Forest Labs (FRX -2.1%) prepares for a showdown with Carl Icahn - and his 6.5% stake in the firm - with 10 new nominees to its board, including 3 new directors. The activist investor is pushing his own nominees to end the extended reign of current directors, and help guide the firm through upcoming patent expirations. Comment! [Healthcare]
- Wednesday, July 13, 2011, 8:02 AM Gilead (GILD) plans to move forward with the sale of generic versions of four HIV treatments in developing countries under the terms of an agreement with a UN-backed patent foundation. New studies show the firm's Truvada HIV pill can prevent the virus transmission, after an early study said the opposite. Comment! [Healthcare]
- Tuesday, July 12, 2011, 3:48 PM Shares of Infinity Pharmaceuticals (INFI +9.6%) pop on above-average volume as the company expands its program to develop new cancer drugs, buying nuisance weeds in western states, unwanted by landowners, but needed by the firm. Comment! [On the Move, Healthcare]
- Friday, July 8, 2011, 1:15 PM UBS cuts estimates on Alexion Pharmaceuticals (ALXN +3.1%), and lowers its price target to $53 from $55, keeping a Neutral rating on the firm. Shares are outgaining all issues listed on the NASDAQ-100. Comment! [On the Move, Healthcare]
- Friday, July 8, 2011, 8:59 AM Geron (GERN) releases positive data from a clinical trial of its human embryonic stem cell-based therapy. JPMorgan initiates coverage with an Overweight rating. Shares +5.4% premarket. Comment! [On the Move, Healthcare]
- Thursday, July 7, 2011, 2:36 PM Based on a long view of profit potential, a number of drug stocks trade at lower valuations than peers, SmartMoney says. After weeding out firms facing major patent issues in coming years, six winners should emerge: Glaxo (GSK +0.4%), Roche (RHHBY.PK -0.9%), Pfizer (PFE -1.9%), Sanofi (SNY -0.7%), Merck (MRK +0.8%), Novartis (NVS +0.3%). Comment! [Quick Ideas, Healthcare]
- Thursday, June 30, 2011, 11:56 AM Corcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its application to market Corlux as a treatment for Cushing's Syndrome. After final approval, Corcept will have seven years to market the drug exclusively. Comment! [On the Move, Healthcare]
- Monday, January 17, 2011, 3:26 PM GlaxoSmithKline (GSK) will take a pharma-record £2.2B ($3.5B) charge in the fourth quarter to settle lawsuits and regulatory fines related to past sales practices. The sum outstrips Pfizer's (PFE) 2009 payment of $2.3B and relates mostly to practices between 1997 and 2004, including those around antidepressants Paxil and Wellbutrin and former diabetes blockbuster Avandia. Comment!
- Tuesday, August 3, 2010, 1:42 PM The Genzyme (GENZ) play is about more than Sanofi-Aventis (SNY) looking for growth. It reflects Big Pharma's push into treating rare illnesses, with the assumption that niche diseases can be a good way to fatten margins, and product pipelines, that are under pressure elsewhere. Comment!
There are no StockTalks on this stock yet.